Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorJONELIUNAITE, Vaiva
dc.contributor.authorGODRON-DUBRASQUET, Astrid
dc.contributor.authorALLARD, Lise
dc.contributor.authorDELMAS, Jean
dc.contributor.authorLLANAS, Brigitte
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHARAMBAT, Jerome
IDREF: 110567358
dc.date.accessioned2025-04-23T08:09:06Z
dc.date.available2025-04-23T08:09:06Z
dc.date.issued2025-03-01
dc.identifier.issn1432-198Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206353
dc.description.abstractEnAutosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disorder. Pathogenic variants in PKD1 and PKD2 genes are the main causes of ADPKD. Biallelic inheritance of pathogenic variants leading to very early-onset manifestations have been described in the literature. A female fetus was prenatally diagnosed with oligohydramnios, bilateral kidney enlargement, and hyperechogenicity at 31 weeks gestational age. The mother was known to have ADPKD from the family history. However, unusually early and very rapid progressive disease after birth led to genetic testing which found two PKD1 variants inherited from both parents. The patient was suffering from refractory arterial hypertension, chronic kidney disease, and respiratory distress leading to off-label use of tolvaptan in the neonatal period. Although the data on tolvaptan use in neonatal polycystic kidney disease remains limited, a 6-year treatment in this patient was well tolerated and may have mitigated kidney growth and disease progression.
dc.language.isoENen_US
dc.subject.enAutosomal dominant polycystic kidney disease
dc.subject.enGenetic testing
dc.subject.enNeonate
dc.subject.enTolvaptan
dc.title.enLong-term tolvaptan therapy in a case of very early-onset polycystic kidney disease
dc.title.alternativePediatr Nephrolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s00467-025-06732-2en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed40025141en_US
bordeaux.journalPediatric Nephrologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-05043516
hal.version1
hal.date.transferred2025-04-23T08:09:08Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pediatric%20Nephrology&rft.date=2025-03-01&rft.eissn=1432-198X&rft.issn=1432-198X&rft.au=JONELIUNAITE,%20Vaiva&GODRON-DUBRASQUET,%20Astrid&ALLARD,%20Lise&DELMAS,%20Jean&LLANAS,%20Brigitte&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée